{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:53:05Z","timestamp":1791312785965,"version":"4.3.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.vaccine.2006.10.009","type":"journal-article","created":{"date-parts":[[2006,10,18]],"date-time":"2006-10-18T20:21:50Z","timestamp":1161202910000},"page":"1214-1224","source":"Crossref","is-referenced-by-count":85,"title":["A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost"],"prefix":"10.1016","volume":"25","author":[{"given":"Yuhong","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Aldaz-Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra M.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Charles","family":"Whitbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Braciale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roselyn J.","family":"Eisenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary H.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart N.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5430","key":"10.1016\/j.vaccine.2006.10.009_bib1","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1126\/science.285.5430.1011","article-title":"Smallpox: setting the research agenda","volume":"285","author":"Shalala","year":"1999","journal-title":"Science"},{"issue":"5672","key":"10.1016\/j.vaccine.2006.10.009_bib2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1126\/science.304.5672.809a","article-title":"Biodefense. Smallpox vaccines: looking beyond the next generation","volume":"304","author":"Enserink","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2006.10.009_bib3","series-title":"Smallpox and its eradication","author":"Fenner","year":"1988"},{"issue":"9","key":"10.1016\/j.vaccine.2006.10.009_bib4","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/nm917","article-title":"Duration of antiviral immunity after smallpox vaccination","volume":"9","author":"Hammarlund","year":"2003","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.vaccine.2006.10.009_bib5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1086\/375825","article-title":"Smallpox vaccination: a review, part II. Adverse events","volume":"37","author":"Fulginiti","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"17\u201318","key":"10.1016\/j.vaccine.2006.10.009_bib6","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/j.vaccine.2005.01.012","article-title":"The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program","volume":"23","author":"Poland","year":"2005","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.vaccine.2006.10.009_bib7","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1073\/pnas.0401165101","article-title":"Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge","volume":"101","author":"Wyatt","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2006.10.009_bib8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature02331","article-title":"Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox","volume":"428","author":"Earl","year":"2004","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.vaccine.2006.10.009_bib9","doi-asserted-by":"crossref","first-page":"7845","DOI":"10.1128\/JVI.79.12.7845-7851.2005","article-title":"Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus","volume":"79","author":"Stittelaar","year":"2005","journal-title":"J Virol"},{"issue":"17","key":"10.1016\/j.vaccine.2006.10.009_bib10","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1016\/j.vaccine.2005.03.029","article-title":"Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge","volume":"24","author":"Empig","year":"2006","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2006.10.009_bib11","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1128\/JVI.02642-05","article-title":"LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox","volume":"80","author":"Saijo","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2006.10.009_bib12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/viro.1999.0096","article-title":"DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge","volume":"266","author":"Hooper","year":"2000","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2006.10.009_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0042-6822(02)00038-7","article-title":"Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates","volume":"306","author":"Hooper","year":"2003","journal-title":"Virology"},{"issue":"9","key":"10.1016\/j.vaccine.2006.10.009_bib14","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1128\/JVI.78.9.4433-4443.2004","article-title":"Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox","volume":"78","author":"Hooper","year":"2004","journal-title":"J Virol"},{"issue":"25\u201326","key":"10.1016\/j.vaccine.2006.10.009_bib15","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1016\/j.vaccine.2004.02.034","article-title":"Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB\/c mice from a lethal intranasal poxvirus challenge","volume":"22","author":"Pulford","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.10.009_bib16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1006\/viro.1998.9516","article-title":"Neutralizing and protective antibodies directed against vaccinia virus envelope antigens","volume":"254","author":"Galmiche","year":"1999","journal-title":"Virology"},{"issue":"19","key":"10.1016\/j.vaccine.2006.10.009_bib17","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1128\/JVI.78.19.10230-10237.2004","article-title":"Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions","volume":"78","author":"Fogg","year":"2004","journal-title":"J Virol"},{"issue":"18","key":"10.1016\/j.vaccine.2006.10.009_bib18","doi-asserted-by":"crossref","first-page":"11724","DOI":"10.1128\/JVI.79.18.11724-11733.2005","article-title":"Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice","volume":"79","author":"Davies","year":"2005","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2006.10.009_bib19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.virol.2005.09.056","article-title":"Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host","volume":"345","author":"Fang","year":"2006","journal-title":"Virology"},{"issue":"12","key":"10.1016\/j.vaccine.2006.10.009_bib20","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1099\/0022-1317-83-12-2915","article-title":"The formation and function of extracellular enveloped vaccinia virus","volume":"83","author":"Smith","year":"2002","journal-title":"J Gen Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2006.10.009_bib21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.virol.2005.09.037","article-title":"Poxvirus entry and membrane fusion","volume":"344","author":"Moss","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2006.10.009_bib22","first-page":"2849","article-title":"Poxviridae: the viruses and their replication","volume":"vol. 2","author":"Moss","year":"2001"},{"key":"10.1016\/j.vaccine.2006.10.009_bib23","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1006\/viro.1994.1405","article-title":"Identification of a vaccinia virus penetration protein","volume":"202","author":"Ichihashi","year":"1994","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2006.10.009_bib24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1006\/viro.1995.1378","article-title":"A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies","volume":"211","author":"Wolffe","year":"1995","journal-title":"Virology"},{"issue":"12","key":"10.1016\/j.vaccine.2006.10.009_bib25","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1073\/pnas.0501103102","article-title":"The 1.51-angstrom structure of the poxvirus L1 protein, a target of potent neutralizing antibodies","volume":"102","author":"Su","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2006.10.009_bib26","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1128\/JVI.56.2.482-488.1985","article-title":"Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus","volume":"56","author":"Rodriguez","year":"1985","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2006.10.009_bib27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0042-6822(90)90381-Z","article-title":"Vaccinia virus induces cell fusion at acid pH and this activity is mediated by the N-terminus of the 14kDa virus envelope protein","volume":"178","author":"Gong","year":"1990","journal-title":"Virology"},{"issue":"12","key":"10.1016\/j.vaccine.2006.10.009_bib28","doi-asserted-by":"crossref","first-page":"10126","DOI":"10.1128\/JVI.72.12.10126-10137.1998","article-title":"The vaccinia virus 14-kilodalton (A27L) fusion protein forms a triple coiled-coil structure and interacts with the 21-kilodalton (A17L) virus membrane protein through a C-terminal alpha-helix","volume":"72","author":"Vazquez","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2006.10.009_bib29","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1128\/JVI.70.6.3753-3762.1996","article-title":"Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene","volume":"70","author":"Roper","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2006.10.009_bib30","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0042-6822(92)90535-W","article-title":"A constitutively expressed vaccinia gene encodes a 42kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope","volume":"188","author":"Engelstad","year":"1992","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2006.10.009_bib31","doi-asserted-by":"crossref","first-page":"7217","DOI":"10.1128\/JVI.66.12.7217-7224.1992","article-title":"Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope","volume":"66","author":"Isaacs","year":"1992","journal-title":"J Virol"},{"issue":"5597","key":"10.1016\/j.vaccine.2006.10.009_bib32","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.1074674","article-title":"Containing bioterrorist smallpox","volume":"298","author":"Halloran","year":"2002","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.vaccine.2006.10.009_bib33","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMsa025075","article-title":"A model for a smallpox-vaccination policy","volume":"348","author":"Bozzette","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2006.10.009_bib34","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrd2059","article-title":"Therapeutic potential of Toll-like receptor 9 activation","volume":"5","author":"Krieg","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"4\u20135","key":"10.1016\/j.vaccine.2006.10.009_bib35","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0264-410X(00)00195-X","article-title":"Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates","volume":"19","author":"Kim","year":"2000","journal-title":"Vaccine"},{"issue":"14","key":"10.1016\/j.vaccine.2006.10.009_bib36","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1097\/01.aids.0000183514.37513.d2","article-title":"CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults","volume":"19","author":"Cooper","year":"2005","journal-title":"Aids"},{"issue":"6","key":"10.1016\/j.vaccine.2006.10.009_bib37","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10875-004-6244-3","article-title":"CPG 7909 an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I\/II study","volume":"24","author":"Cooper","year":"2004","journal-title":"J Clin Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2006.10.009_bib38","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1128\/JVI.79.10.6260-6271.2005","article-title":"Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R","volume":"79","author":"Aldaz-Carroll","year":"2005","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2006.10.009_bib39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.virol.2005.07.006","article-title":"Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene","volume":"341","author":"Aldaz-Carroll","year":"2005","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.vaccine.2006.10.009_bib40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0378-1119(91)90171-7","article-title":"Enhanced secretion from insect cells of a foreign protein fused to the honeybee melittin signal peptide","volume":"98","author":"Tessier","year":"1991","journal-title":"Gene"},{"issue":"Part 5","key":"10.1016\/j.vaccine.2006.10.009_bib41","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1099\/0022-1317-83-5-1059","article-title":"Administration to mice of a monoclonal antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions","volume":"83","author":"Ramirez","year":"2002","journal-title":"J Gen Virol"},{"issue":"Pt 10","key":"10.1016\/j.vaccine.2006.10.009_bib42","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1099\/vir.0.81090-0","article-title":"Ectromelia virus: the causative agent of mousepox","volume":"86","author":"Esteban","year":"2005","journal-title":"J Gen Virol"},{"issue":"17","key":"10.1016\/j.vaccine.2006.10.009_bib43","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0264-410X(99)00526-5","article-title":"CpG DNA induces stronger immune responses with less toxicity than other adjuvants","volume":"18","author":"Weeratna","year":"2000","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2006.10.009_bib44","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1046\/j.1440-1711.2003.01135.x","article-title":"CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB\/c mice","volume":"81","author":"Weeratna","year":"2003","journal-title":"Immunol Cell Biol"},{"issue":"3","key":"10.1016\/j.vaccine.2006.10.009_bib45","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.4049\/jimmunol.162.3.1611","article-title":"CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming","volume":"162","author":"Kovarik","year":"1999","journal-title":"J Immunol"},{"issue":"18","key":"10.1016\/j.vaccine.2006.10.009_bib46","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/S0264-410X(99)00443-0","article-title":"CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans","volume":"18","author":"Davis","year":"2000","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2006.10.009_bib47","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.vaccine.2004.07.014","article-title":"Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response","volume":"23","author":"Siegrist","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.10.009_bib48","unstructured":"Poxvirus Bioinformatics Resource Center, http:\/\/www.poxvirus.org\/. 2006 [accessed September 2006]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06011145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06011145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T12:30:10Z","timestamp":1683635410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X06011145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S0264410X06011145"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2006.10.009","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}